Video Shorts

1:54
Brensocatib Safe for Bronchiectasis
a year ago
by
James Chalmers, MBChB, PhD(+1 more)

1:30
Don't Miss a Beat: Vericiguat and the VICTOR Trial, With Javed Butler, MD
a year ago
by
Muthiah Vaduganathan, MD, MPH(+1 more)

2:41
A New Era of Disease-Modifying Therapy for Bronchiectasis
a year ago
by
Albert Rizzo, MD(+1 more)

1:24
A New Era of Management in C3 Glomerulopathy, with Sayna Norouzi, MD
a year ago
by
Sayna Norouzi, MD

1:28
New Drug Clears Chronic Hand Eczema in 16 Weeks
a year ago
by
Linda Stein Gold, MD

1:50
Diabetes Dialogue: Screening for MASH is Easier Than You Think
a year ago
by
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES(+1 more)

1:52
Nephrologist Reacts to Pegcetacoplan’s Approval in C3 Glomerulopathy
a year ago
by
Sayna Norouzi, MD

1:30
Liver Lineup: How Semaglutide Improves Liver Health Beyond Weight Loss
a year ago
by
Nancy Reau, MD(+2 more)

2:13
Preview of Medical Sisterhood, With Laura Ferris, MD, PhD
a year ago
by
Mona Shahriari, MD, FAAD(+1 more)

1:46
ESSENCE and Semaglutide 2.4 mg for MASH
a year ago
by
Arun Sanyal, MD

2:10
ATTAIN-1 Topline Results Shed Light on Orforglipron in Obesity
a year ago
by
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES(+1 more)

0:32
Short #4
a year ago
by
Silas Inman
Advertisement
Advertisement
Trending on HCPLive
1
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
2
EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis
3
AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD
4
Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis
5
